The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Medical Device CROs Market (2nd Edition), 2020 - 2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    April 2020

  • Pages
    405

  • View Count
    7267

Example Insights

Medical-Device-CROs-Market-Context	Medical-Device-CROs-Market-Landscape Medical-Device-CROs-Market-List-of-CROs
Medical-Device-CROs-Market-Distribution-by-geography Medical-Device-CROs-Market-Benchmark-analysis Medical-Device-CROs-Market-Mergers-and-acquisitions
Medical-Device-CROs-Market-Brand-positioning-matrix 	Medical-Device-CROs-Market-Forecast Medical-Device-CROs-Market-Futuer-forecast

 

Overview

According to the Food and Drug Administration’s Center for Devices and Radiological Health (CDRH), at present, there are close to 175,000 types of medical devices available in the US. In fact, since 2019, the USFDA has approved close to 55 medical devices. Further, over 7,000 medical device focused clinical trials have been registered worldwide. In this context, our estimates suggest that total revenues from global sales of medical devices is likely to be around USD 450 billion in 2020. The medical devices market currently represents a large segment of the healthcare industry and is projected to continue to grow over the coming years. However, only a limited proportion of device developers claim to have the necessary resources and technical expertise to develop and conduct clinical research, in-house. This is mostly attributed to the high cost of acquiring the necessary infrastructure / capabilities for such research initiatives, making it difficult for companies with limited finances to undertake and manage elaborate R&D initiatives by themselves. In addition, regulations governing the review (of safety and efficacy) and approval of such devices are gradually becoming more stringent. For instance, the EU’s revised Medical Device Regulation (MDR) have rendered medical devices subject to rigorous quality assessments, necessitating a certain type of expertise and affiliated resources. Although the COVID-19 pandemic has delayed the enforcement of these guidelines to May 2021, device developers still need to establish the necessary means to address this upcoming challenge. In this regard, outsourcing has been shown to offer a number of benefits, including cost savings and expediting time to market. As a result, medical device developers are now increasingly outsourcing significant parts of their respective clinical research efforts and regulatory affairs management to contract research organizations (CROs). 

The medical device CRO market is highly fragmented, featuring the presence of well-established players (which contribute to a majority share of the overall revenues), mid-sized firms and a number of new entrants, offering niche expertise. In fact, over 50 medical device focused CROs have been established since 2010. It is worth noting that, in order to cope with modern day challenges, CROs have adopted emerging technologies / operating principles, such as big data analysis, artificial intelligence (AI) and real-world evidence, and are gradually working towards improving their approach to research. For this purpose, many traditional CROs have established strategic business relations with information technology (IT) and data management solutions providers. In addition, this industry has witnessed significant merger and acquisition activity in the last ten years, with several smaller businesses being acquired in efforts to grow the service portfolios / capabilities of more established firms. According to experts, the medical device CRO industry is anticipated to witness a similar growth trajectory as that of the pharmaceutical CRO market, in the coming 5-10 years.

Scope of the Report

The ‘Medical Device CROs Market (2nd Edition), 2020-2030’ report features an extensive study of the current market landscape and future opportunities of contract research service providers focused on medical devices. The study also features an in-depth analysis, highlighting the capabilities of the various stakeholders engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of medical device CROs, along with information on year of establishment, company size, location of headquarters, type of service offered by [A] clinical service providers  (biostatistics, consulting, clinical operations, post marketing surveillance / studies, quality assurance, regulatory affairs management, reimbursement and training), [B] preclinical service providers (consulting, biocompatibility testing, materials characterization and analytical testing, preclinical trials support, sterility testing and microbiology testing, and training) and [C] stand-alone service providers (consulting, training, quality assurance, clinical operations, and regulatory affairs management). 
  • An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), and Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe. 
  • Elaborate profiles of key players that specialize in offering services for both clinical and preclinical stage development of medical devices. Each profile features an overview of the company, along with information on year of establishment, number of employees, location of headquarters, presence across key geographies, target therapeutic areas, financial details (if available), medical device focused service portfolio, and an informed future outlook.
  • An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers engaged in this domain, based on information gathered via secondary research (for top-ten medical device players) and primary research.
  • A competitive benchmarking, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups, and providing a means for stakeholders to identify ways to gain a competitive advantage in the industry.
  • A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different device classes.
  • A detailed geographical clinical trial analysis of ongoing and planned studies related to medical devices, along with information on number of registered trials, location of trial site, current status of trials, current phase of trial, type of sponsor, target therapeutic area(s) and number of patients enrolled.
  • A detailed analysis of the mergers and acquisitions that have taken place in this domain during the period 2015-2020, highlighting geographical activity. The analysis also features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain. 
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract research services to medical device developers. 
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall medical device CRO industry.
  • An elaborate discussion on the future opportunities / trends for the medical device outsourcing market that are likely to influence the growth of this domain over the coming years.

One of the key objectives of this report was to evaluate the existing market size and the future growth potential within the medical device CROs domain. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] different phases of development (clinical and preclinical) [B] types of clinical services offered (clinical trial management, data management, regulatory affairs management, consulting and others) [C] types of preclinical services (biocompatibility testing, sterility and microbiology testing, material characterization and analytical services and others) [D] device class (class I, class II and class III), and [E] target therapeutic area (bone disorders, cardiovascular disorders, CNS disorders, metabolic disorders, oncological disorders, ophthalmic disorders, pain management, respiratory disorders, sleeping disorders and others), and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. In addition, the report discusses the impact of the recent COVID-19 pandemic on the overall medical device industry, along with providing details related to the future market opportunity for medical device CROs.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following stakeholders: 

  • Lajos Sarosi, Chief Executive Officer and Co-founder, HungaroTrial
  • Christian Wolflehner, Managing Director, Clinical Trial Specialist, CW Research & Management
  • Troy Mccall, Chief Operating Officer, CROMSOURCE
  • Nazish Urooj, Senior manager, Medical & Clinical Operations, Metrics Research
  • Alexa Foltin-Mertgen, Business Development Manager, AtoZ-CRO
  • Tania Persson, Business Development Manager, A+ Science
  • C. Omprakash, Technical Director and Partner, Vyomus Consulting  
  • Anonymous

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the medical device CROs market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a brief introduction to medical devices, highlighting key historical and development milestones, and classification of such devices. It also provides a general overview of the concept of CROs, featuring a discussion on the historical evolution of contract research services market in the medical device domain. Further, the chapter presents details related to the various types of CROs that operate within the medical device market and the different types of services they usually offer. It further lists the advantages as well as challenges associated with outsourcing medical device research and clinical operations to contract service providers, along with the key parameters that need to be considered while selecting a CRO partner.

Chapter 4 provides a detailed review of the overall landscape of medical device CROs, along with information on year of establishment, company size, location of headquarters, type of service offered by [A] clinical service providers (biostatistics, consulting, clinical operations, post marketing surveillance / studies, quality assurance, regulatory affairs management, reimbursement and training), [B] preclinical service providers (consulting, biocompatibility testing, materials characterization and analytical testing, preclinical trials support, sterility testing and microbiology testing, and training) and [C] stand-alone service providers (consulting, training, quality assurance, clinical operations, and regulatory affairs management).

Chapter 5 features a discussion on the various guidelines established by major regulatory bodies for medical device approvals across North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), and Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.  

Chapter 6 features detailed profiles of key players that specialize in offering services for both clinical and preclinical stage development of medical devices. Each profile features an overview of the company, along with information on year of establishment, number of employees, location of headquarters, presence across key geographies, target therapeutic area, financial details (if available), medical device focused service portfolio, and an informed future outlook.

Chapter 7 features an analysis on the key performance indicators used by sponsor companies to evaluate service providers engaged in this domain, based on information gathered via secondary research (for top-ten medical device players), as well as credible inputs from primary research.

Chapter 8 presents a competitive benchmarking of the various players engaged in this domain. It highlights the capabilities of small-sized, mid-sized and large companies in terms of their expertise in medical device services. The analysis allows companies to compare their existing capabilities within and beyond their respective peer groups and providing a means for stakeholders to identify ways to gain a competitive advantage in the industry.

Chapter 9 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of strength of service portfolio) highlighting the current perceptions regarding their proprietary brands across different device classes.

Chapter 10 presents a detailed geographical clinical trial analysis of ongoing and planned studies related to medical devices, along with information on number of registered trials, location of trial site, current status of trials, current phase of trial, type of sponsor, target therapeutic area(s) and number of patients enrolled.

Chapter 11 features a detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2015-2020, based on parameters such as year of acquisition, type of acquisition, geographical location of the acquirer and the acquired company, type of company and key value drivers. The analysis also features an ownership change matrix, providing insights on the involvement of private and public sector entities in this domain. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.

Chapter 12 presents insights from the survey conducted for this study. We invited over 200 stakeholders that provide CRO services to medical device developers. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services, prevalent trends and associated commercial potential of this domain.

Chapter 13 presents a likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different phases of development (clinical and preclinical) [B] types of clinical services offered (clinical trial management, data management, regulatory affairs management, consulting and others) [C] types of preclinical services (biocompatibility testing, sterility and microbiology testing, material characterization and analytical services and others) [D] device class (class I, class II and class III), and [E] target therapeutic area (bone disorders, cardiovascular disorders, CNS disorders, metabolic disorders, oncological disorders, ophthalmic disorders, pain management disorders, respiratory disorders, sleeping disorders and others), and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 14 highlights the effect of coronavirus outbreak on the global medical device industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for CROs. In addition, it includes a brief section on strategies and action plans that medical device companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 15 provides a discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall medical devices CRO industry.

Chapter 16 presents a discussion on the upcoming opportunities / trends of medical device contract services market that are likely to impact the future evolution of this domain over the coming years. These include (but not limited to) growth in number of connected devices, adoption of data analytics and real-time monitoring solutions, growing need for cloud-based data storage solutions and introduction of real-world evidence. 

Chapter 17 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. In this chapter, we have presented the details of interviews held with Lajos Sarosi (Chief Executive Officer and Co-founder, HungaroTrial), Troy Mccall (Chief Operating Officer, CROMSOURCE), Christian Wolflehner (Managing Director, Clinical Trial Specialist, CW Research & Management), Nazish Urooj (Senior manager, Medical & Clinical Operations, Metrics Research), Alexa Foltin-Mertgen (Business Development Manager, AtoZ-CRO), Tania Persson (Business Development Manager, A+ Science) and C. Omprakash (Technical Director and Partner, Vyomus Consulting) and Anonymous.

Chapter 18 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Medical Devices
3.2.1. Historical Evolution of Medical Devices
3.2.2. Classification of Medical Devices
3.3. Overview of Contract Research Organizations (CROs)
3.3.1. Evolution of CROs
3.4. Role of CROs in the Medical Device Industry

3.5. Types of Medical Device CROs
3.6. Types of Services Offered by CROs
3.7. Advantages of Outsourcing Drug Discovery Operations to CROs
3.8. Risks and Challenges Associated with Outsourcing 
3.9. Key Considerations for Selecting a Suitable CRO Partner 

4. MEDICAL DEVICE CROS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Medical Device CROs: Clinical Service Providers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Service Offered

4.3. Medical Device CROs: Preclinical Service Providers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Analysis by Type of Service Offered

4.4. Medical Device CROs: Standalone Service Providers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Company Size and Location of Headquarters
4.4.5. Analysis by Type of Service Offered

5. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
5.1. Chapter Overview
5.2. General Regulatory and Reimbursement Guidelines for Medical Devices

5.3. Regulatory and Reimbursement Landscape in North America
5.3.1. The US Scenario
5.3.1.1. Regulatory Authority
5.3.1.2. Review / Approval Process
5.3.1.3. Reimbursement Landscape
5.3.1.3.1. Payer Mix
5.3.1.3.2. Reimbursement Process

5.3.2. The Canadian Scenario
5.3.2.1. Regulatory Authority
5.3.2.2. Review / Approval Process
5.3.2.3. Reimbursement Landscape
5.3.2.3.1. Payer Mix
5.3.2.3.2. Reimbursement Process

5.3.3. The Mexican Scenario
5.3.3.1. Regulatory Authority
5.3.3.2. Review / Approval Process
5.3.3.3. Reimbursement Landscape
5.3.3.3.1. Payer Mix

5.4. Regulatory and Reimbursement Landscape in Europe
5.4.1. Overall Scenario
5.4.1.1. Overall Regulatory Authority
5.4.1.2. Overall Review / Approval Process

5.4.2. The UK Scenario
5.4.2.1. Regulatory Authority
5.4.2.2. Review / Approval Process
5.4.2.3. Reimbursement Landscape
5.4.2.3.1. Payer Mix
5.4.2.3.2. Reimbursement Process

5.4.3. The French Scenario
5.4.3.1. Regulatory Authority
5.4.3.2. Review / Approval Process
5.4.3.3. Reimbursement Landscape
5.4.3.3.1. Payer Mix
5.4.3.3.2. Reimbursement Process

5.4.4. The German Scenario
5.4.4.1. Regulatory Authority
5.4.4.2. Review / Approval Process
5.4.4.3. Reimbursement Landscape
5.4.4.3.1. Payer Mix
5.4.4.3.2. Reimbursement Process

5.4.5. The Italian Scenario
5.4.5.1. Regulatory Authority
5.4.5.2. Review / Approval Process
5.4.5.3. Reimbursement Landscape
5.4.5.3.1. Payer Mix
5.4.5.3.2. Reimbursement Process

5.4.6. The Spanish Scenario
5.4.6.1. Regulatory Authority
5.4.6.2. Review / Approval Process
5.4.6.3. Reimbursement Landscape
5.4.6.3.1. Payer Mix
5.4.6.3.2. Reimbursement Process

5.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
5.5.1. The Australian Scenario
5.5.1.1. Regulatory Authority
5.5.1.2. Review / Approval Process
5.5.1.3. Reimbursement Landscape
5.5.1.3.1. Payer Mix
5.5.1.3.2. Reimbursement Process

5.5.2. The Brazilian Scenario
5.5.2.1. Regulatory Authority
5.5.2.2. Review / Approval Process
5.5.2.3. Reimbursement Landscape
5.5.2.3.1. Payer Mix
5.5.2.3.2. Reimbursement Process

5.5.3. The Chinese Scenario
5.5.3.1. Regulatory Authority
5.5.3.2. Review / Approval Process
5.5.3.3. Reimbursement Landscape
5.5.3.3.1. Payer Mix
5.5.3.3.2. Reimbursement Process

5.5.4. The Indian Scenario
5.5.4.1. Regulatory Authority
5.5.4.2. Review / Approval Process
5.5.4.3. Reimbursement Landscape
5.5.4.3.1. Payer Mix

5.5.5. The Israeli Scenario
5.5.5.1. Regulatory Authority
5.5.5.2. Review / Approval Process
5.5.5.3. Reimbursement Landscape
5.5.5.3.1. Payer Mix

5.5.6. The Japanese Scenario
5.5.6.1. Regulatory Authority
5.5.6.2. Review / Approval Process
5.5.6.3. Reimbursement Landscape
5.5.6.3.1. Payer Mix
5.5.6.3.2. Reimbursement Process

5.5.7. The New Zealand Scenario
5.5.7.1. Regulatory Authority
5.5.7.2. Review / Approval Process
5.5.7.3. Reimbursement Landscape
5.5.7.3.1. Payer Mix
5.5.7.3.2. Reimbursement Process

5.5.8. The Singapore Scenario
5.5.8.1. Regulatory Authority
5.5.8.2. Review / Approval Process
5.5.8.3. Reimbursement Landscape
5.5.8.3.1. Payer Mix
5.5.8.3.2. Reimbursement Process

5.5.9. The South Korean Scenario
5.5.9.1. Regulatory Authority
5.5.9.2. Review / Approval Process
5.5.9.3. Reimbursement Landscape
5.5.9.3.1. Payer Mix
5.5.9.3.2. Reimbursement Process

5.5.10. The South African Scenario
5.5.10.1. Regulatory Authority
5.5.10.2. Review / Approval Process
5.5.10.3. Reimbursement Landscape

5.5.11. The Taiwan Scenario
5.5.11.1. Regulatory Authority
5.5.11.2. Review / Approval Process
5.5.11.3. Reimbursement Landscape
5.5.11.3.1. Payer Mix
5.5.11.3.2. Reimbursement Process

5.5.12. The Thailand Scenario
5.5.12.1. Regulatory Authority
5.5.12.2. Review / Approval Process
5.5.12.3. Reimbursement Landscape

5.6. Comparison of Regional Regulatory Control
5.7. Concluding Remarks

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Avania (Formerly known as Factory CRO)
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Future Outlook

6.3. Charles River Laboratories
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Future Outlook

6.4. Clinlogix
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Future Outlook

6.5. CROMSOURCE
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Future Outlook

6.6. CSSi LifeSciences
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Future Outlook

6.7. Eurofins Medical device Testing
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Future Outlook

6.8. genae
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Future Outlook

6.9. IMARC Research
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Future Outlook

6.10. IQVIA
6.10.1. Company Overview
6.10.2. Service Portfolio
6.10.3. Future Outlook

6.11. Medpace
6.11.1. Company Overview
6.11.2. Service Portfolio
6.11.3. Future Outlook

6.12. NAMSA
6.12.1. Company Overview
6.12.2. Service Portfolio
6.12.3. Future Outlook

6.13. Qserve Group
6.13.1. Company Overview
6.13.2. Service Portfolio
6.13.3. Future Outlook

6.14. Regulatory and Clinical Research Institute (Now a part of Covance)
6.14.1. Company Overview
6.14.2. Service Portfolio
6.14.3. Future Outlook

6.15. WuXi AppTec
6.15.1. Company Overview
6.15.2. Service Portfolio
6.15.3. Future Outlook

7. MEDICAL DEVICE DEVELOPER AND CRO RELATIONSHIPS: KEY VALUE DRIVERS AND PERFORMANCE INDICATORS
7.1. Chapter Overview
7.2. Definition and Importance of Key Performance Indicators (KPIs)
7.3. Key Considerations for Selection of KPIs 
7.4. Types of KPIs
7.4.1. Financial Indicators
7.4.1.1. Most Important KPIs
7.4.1.1.1. Financial Stability
7.4.1.1.2. Cost of Services Offered
7.4.1.1.3. Comparative Analysis of Financial Indicators

7.4.1.2. Industry Perspective
7.4.1.2.1. Sponsors’ (Big Pharma) Perspective
7.4.1.2.2. Contract Service Providers’ Perspective

7.4.2. Process and Capability Indicators
7.4.2.1. Most Important KPIs
7.4.2.1.1. Proximity to Sponsor
7.4.2.1.2. Capability to Innovate / Mitigate Risk
7.4.2.1.3. Strength of Service Portfolio
7.4.2.1.4. Comparative Analysis of Process / Capability Indicators

7.4.2.2. Industry Perspective
7.4.2.2.1. Sponsors’ (Big Pharma) Perspective
7.4.2.2.2. Contract Service Providers’ Perspective

7.4.3. Market Reputation Indicators
7.4.3.1. Most Important KPIs
7.4.3.1.1. Flexibility / Adaptability
7.4.3.1.2. Time Management
7.4.3.1.3. Quality / Reliability
7.4.3.1.4. Regulatory Compliance / Track Record
7.4.3.1.5. Comparative Analysis of Market Reputation Indicators

7.4.3.2. Industry Perspective
7.4.3.2.1. Sponsors’ (Big Pharma) Perspective
7.4.3.2.2. Contract Service Providers’ Perspective

7.5. Comparison of Key Performance Indicators
7.6. Concluding Remarks

8. COMPETITIVE BENCHMARKING
8.1. Chapter Overview
8.2. Methodology
8.3. Benchmark Analysis: Peer Groups
8.3.1. North America, Peer Group I
8.3.2. North America, Peer Group II
8.3.3. North America, Peer Group III
8.3.4. Europe, Peer Group IV
8.3.5. Europe, Peer Group V
8.3.6. Asia Pacific, Peer Group VI
8.3.7. Asia Pacific, Peer Group VII

9. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
9.1. Chapter Overview 
9.2. Scope and Methodology
9.3. Brand Positioning Matrix: FMD K&L
9.4. Brand Positioning Matrix: ICON
9.5. Brand Positioning Matrix: NAMSA
9.6. Brand Positioning Matrix: PAREXEL International
9.7. Brand Positioning Matrix: PPD

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Medical Devices: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Therapeutic Area
10.3.5. Analysis by Geography
10.3.6. Geographical Analysis by Trial Status
10.4. Analysis by Type of Sponsor

10.5. Medical Devices: Analysis of Enrolled Patient Population
10.5.1. Analysis by Trial Registration Year
10.5.2. Analysis by Trial Status
10.5.3. Analysis by Trial Phase
10.5.4. Analysis by Therapeutic Area
10.5.5. Analysis by Location of Trial Site

11. MERGERS AND ACQUISITIONS
11.1. Chapter Overview
11.2. Merger and Acquisition Models
11.3. Medical Device CROs: Mergers and Acquisitions
11.3.1. Analysis by Year of Merger / Acquisition
11.3.2. Analysis by Type of Merger / Acquisition
11.3.3. Regional Analysis
11.3.3.1. Continent-wise Distribution
11.3.3.2. Intercontinental and Intracontinental Deals
11.3.3.3. Country-wise Distribution

11.3.4. Ownership Change Matrix
11.3.5. Analysis by Type of Company
11.3.6. Analysis by Key Value Drivers
11.3.6.1. Analysis by Key Value Drivers and Year of Acquisition

12. SURVEY INSIGHTS
12.1. Chapter Overview
12.2. Designation of Respondents
12.3. Type of Service Offered
12.4. Target Therapeutic Area
12.5. Number of Annual Projects
12.6. Market Opportunity

13. MARKET SIZING AND FORECAST
13.1. Chapter Overview
13.2. Assumptions and Forecast Methodology

13.3. Overall Medical Device CRO Market, 2020-2030
13.3.1. Medical Device CRO Market, 2020-2030: Distribution by Therapeutic Area
13.3.2. Medical Device CRO Market, 2020-2030: Distribution by Scale of Operation
13.3.3. Medical Device CRO Market, 2020-2030: Distribution by Device Class
13.3.4. Medical Device CRO Market, 2020-2030: Distribution by Type of Clinical Service Offered
13.3.5. Medical Device CRO Market, 2020-2030: Distribution by Type of Preclinical Servce Offered
13.3.6. Medical Device CRO Market, 2020-2030: Distribution by Geography

13.4. Medical Device CRO Market in North America, 2020-2030
13.4.1. Medical Device CRO Market in North America, 2020-2030: Distribution by Therapeutic Area
13.4.1.1. Medical Device CRO Market for Bone Disorders in North America, 2020-2030
13.4.1.2. Medical Device CRO Market for Cardiovascular Disorders in North America, 2020-2030
13.4.1.3. Medical Device CRO Market for CNS Disorders in North America, 2020-2030
13.4.1.4. Medical Device CRO Market for Metabolic Disorders in North America, 2020-2030
13.4.1.5. Medical Device CRO Market for Oncological Disorders in North America, 2020-2030
13.4.1.6. Medical Device CRO Market for Ophthalmic Disorders in North America, 2020-2030
13.4.1.7. Medical Device CRO Market for Pain Management Disorders in North America, 2020-2030
13.4.1.8. Medical Device CRO Market for Respiratory Disorders in North America, 2020-2030
13.4.1.9. Medical Device CRO Market for Sleeping Disorders in North America, 2020-2030
13.4.1.10. Medical Device CRO Market for Other Therapeutic Areas in North America, 2020-2030

13.4.2. Medical Device CRO Market in North America, 2020-2030: Distribution by Device Class
13.4.2.1. Medical Device CRO Market for Class I Devices in North America, 2020-2030
13.4.2.2. Medical Device CRO Market for Class II Devices in North America, 2020-2030
13.4.2.3. Medical Device CRO Market for Class III Devices in North America, 2020-2030

13.4.3. Medical Device CRO Market in North America, 2020-2030: Distribution by Type of Clinical Service Offered
13.4.3.1. Medical Device CRO Market for Clinical Trial Management Services in North America, 2020-2030
13.4.3.2. Medical Device CRO Market for Consulting Services in North America, 2020-2030
13.4.3.3. Medical Device CRO Market for Data Management Services in North America, 2020-2030
13.4.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in North America, 2020-2030
13.4.3.5. Medical Device CRO Market for Other Clinical Services in North America, 2020-2030

13.4.4. Medical Device CRO Market in North America, 2020-2030: Distribution by Type of Preclinical Service Offered
13.4.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in North America, 2020-2030
13.4.4.2. Medical Device CRO Market for Biocompatibility Testing Services in North America, 2020-2030
13.4.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in North America, 2020-2030
13.4.4.4. Medical Device CRO Market for Other Preclinical Services in North America, 2020-2030

13.5. Medical Device CRO Market in Europe, 2020-2030
13.5.1. Medical Device CRO Market in Europe, 2020-2030: Distribution by Therapeutic Area
13.5.1.1. Medical Device CRO Market for Bone Disorders in Europe, 2020-2030
13.5.1.2. Medical Device CRO Market for Cardiovascular Disorders in Europe, 2020-2030
13.5.1.3. Medical Device CRO Market for CNS Disorders in Europe, 2020-2030
13.5.1.4. Medical Device CRO Market for Metabolic Disorders in Europe, 2020-2030
13.5.1.5. Medical Device CRO Market for Oncological Disorders in Europe, 2020-2030
13.5.1.6. Medical Device CRO Market for Ophthalmic Disorders in Europe, 2020-2030
13.5.1.7. Medical Device CRO Market for Pain Management Disorders in Europe, 2020-2030
13.5.1.8. Medical Device CRO Market for Respiratory Disorders in Europe, 2020-2030
13.5.1.9. Medical Device CRO Market for Sleeping Disorders in Europe, 2020-2030
13.5.1.10. Medical Device CRO Market for Other Therapeutic Areas in Europe, 2020-2030

13.5.2. Medical Device CRO Market in Europe, 2020-2030: Distribution by Device Class
13.5.2.1. Medical Device CRO Market for Class I Devices in Europe, 2020-2030
13.5.2.2. Medical Device CRO Market for Class II Devices in Europe, 2020-2030
13.5.2.3. Medical Device CRO Market for Class III Devices in Europe, 2020-2030

13.5.3. Medical Device CRO Market in Europe, 2020-2030: Distribution by Type of Clinical Service Offered
13.5.3.1. Medical Device CRO Market for Clinical Trial Management Services in Europe, 2020-2030
13.5.3.2. Medical Device CRO Market for Consulting Services in Europe, 2020-2030
13.5.3.3. Medical Device CRO Market for Data Management Services in Europe, 2020-2030
13.5.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in Europe, 2020-2030
13.5.3.5. Medical Device CRO Market for Other Clinical Services in Europe, 2020-2030

13.5.4. Medical Device CRO Market in Europe, 2020-2030: Distribution by Type of Preclinical Service Offered
13.5.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in Europe, 2020-2030
13.5.4.2. Medical Device CRO Market for Biocompatibility Testing Services in Europe, 2020-2030
13.5.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in Europe, 2020-2030
13.5.4.4. Medical Device CRO Market for Other Preclinical Services in Europe, 2020-2030

13.6. Medical Device CRO Market in Asia-Pacific, 2020-2030
13.6.1. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Therapeutic Area
13.6.1.1. Medical Device CRO Market for Bone Disorders in Asia-Pacific, 2020-2030
13.6.1.2. Medical Device CRO Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030
13.6.1.3. Medical Device CRO Market for CNS Disorders in Asia-Pacific, 2020-2030
13.6.1.4. Medical Device CRO Market for Metabolic Disorders in Asia-Pacific, 2020-2030
13.6.1.5. Medical Device CRO Market for Oncological Disorders in Asia-Pacific, 2020-2030
13.6.1.6. Medical Device CRO Market for Ophthalmic Disorders in Asia-Pacific, 2020-2030
13.6.1.7. Medical Device CRO Market for Pain Management Disorders in Asia-Pacific, 2020-2030
13.6.1.8. Medical Device CRO Market for Respiratory Disorders in Asia-Pacific, 2020-2030
13.6.1.9. Medical Device CRO Market for Sleeping Disorders in Asia-Pacific, 2020-2030
13.6.1.10. Medical Device CRO Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030

13.6.2. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Device Class
13.6.2.1. Medical Device CRO Market for Class I Devices in Asia-Pacific, 2020-2030
13.6.2.2. Medical Device CRO Market for Class II Devices in Asia-Pacific, 2020-2030
13.6.2.3. Medical Device CRO Market for Class III Devices in Asia-Pacific, 2020-2030

13.6.3. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Type of Clinical Service Offered
13.6.3.1. Medical Device CRO Market for Clinical Trial Management Services in Asia-Pacific, 2020-2030
13.6.3.2. Medical Device CRO Market for Consulting Services in Asia-Pacific, 2020-2030
13.6.3.3. Medical Device CRO Market for Data Management Services in Asia-Pacific, 2020-2030
13.6.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in Asia-Pacific, 2020-2030
13.6.3.5. Medical Device CRO Market for Other Clinical Services in Asia-Pacific, 2020-2030

13.6.4. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Type of Preclinical Service Offered
13.6.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in Asia-Pacific, 2020-2030
13.6.4.2. Medical Device CRO Market for Biocompatibility Testing Services in Asia-Pacific, 2020-2030
13.6.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in Asia-Pacific, 2020-2030
13.6.4.4. Medical Device CRO Market for Other Preclinical Services in Asia-Pacific, 2020-2030

13.7. Medical Device CRO Market in Rest of the World, 2020-2030
13.7.1. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Therapeutic Area
13.7.1.1. Medical Device CRO Market for Bone Disorders in Rest of the World, 2020-2030
13.7.1.2. Medical Device CRO Market for Cardiovascular Disorders in Rest of the World, 2020-2030
13.7.1.3. Medical Device CRO Market for CNS Disorders in Rest of the World, 2020-2030
13.7.1.4. Medical Device CRO Market for Metabolic Disorders in Rest of the World, 2020-2030
13.7.1.5. Medical Device CRO Market for Oncological Disorders in Rest of the World, 2020-2030
13.7.1.6. Medical Device CRO Market for Ophthalmic Disorders in Rest of the World, 2020-2030
13.7.1.7. Medical Device CRO Market for Pain Management Disorders in Rest of the World, 2020-2030
13.7.1.8. Medical Device CRO Market for Respiratory Disorders in Rest of the World, 2020-2030
13.7.1.9. Medical Device CRO Market for Sleeping Disorders in Rest of the World, 2020-2030
13.7.1.10. Medical Device CRO Market for Other Therapeutic Areas in Rest of the World, 2020-2030

13.7.2. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Device Class
13.7.2.1. Medical Device CRO Market for Class I Devices in Rest of the World, 2020-2030
13.7.2.2. Medical Device CRO Market for Class II Devices in Rest of the World, 2020-2030
13.7.2.3. Medical Device CRO Market for Class III Devices in Rest of the World, 2020-2030

13.7.3. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Type of Clinical Service Offered
13.7.3.1. Medical Device CRO Market for Clinical Trial Management Services in Rest of the World, 2020-2030
13.7.3.2. Medical Device CRO Market for Consulting Services in Rest of the World, 2020-2030
13.7.3.3. Medical Device CRO Market for Data Management Services in Rest of the World, 2020-2030
13.7.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in Rest of the World, 2020-2030
13.7.3.5. Medical Device CRO Market for Other Clinical Services in Rest of the World, 2020-2030

13.7.4. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Type of Preclinical Service Offered
13.7.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in Rest of the World, 2020-2030
13.7.4.2. Medical Device CRO Market for Biocompatibility Testing Services in Rest of the World, 2020-2030
13.7.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in Rest of the World, 2020-2030
13.7.4.4. Medical Device CRO Market for Other Preclinical Services in Rest of the World, 2020-2030

14. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
14.1. Chapter Overview
14.2. Impact of Coronavirus Upsurge on Medical Device Industry
14.2.1. Short Term Impact
14.2.2. Long Term Impact
14.3. Future Strategies and Action Plans: A Bird’s Eye View

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Concluding Remarks

16. FUTURE TRENDS AND OPPORTUNITIES
16.1. Chapter Overview
16.2. Anticipated Growth in Number of Connected Devices
16.3. Adoption of Data Analytics and Real-Time Monitoring Solutions
16.4. Need for Cloud-based Computing and Storage Solutions 
16.5. Growing Need for Real World Evidence for Regulatory Approval
16.6. Concluding Remarks

17. INTERVIEW TRANSCRIPTS
17.1. Chapter Overview
17.2. Lajos Sarosi, Chief Executive Officer and Co-founder, HungaroTrial
17.3. Troy McCall, Chief Operating Officer, CROMSOURCE
17.4. Christian Wolflehner, Managing Director and Clinical Trial Specialist, CW Research & Management
17.5. Nazish Urooj, Senior manager, Medical & Clinical Operations, Metrics Research
17.6. Alexa Foltin-Mertgen, Business Development Manager, AtoZ-CRO
17.7. Tania Persson, Business Development Manager, A+ Science
17.8. C. Omprakash, Technical Director and Partner, Vyomus Consulting
17.9. Anonymous

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Historical Timeline of Medical Device Inventions
Figure 3.2 Medical Device: Development Process and Timeline
Figure 3.3 Type of CROs Engaged in the Medical Device Market
Figure 3.4 Services Offered by CROs
Figure 3.5 Risks / Challenges Associated with Outsourcing Operations to CROs
Figure 4.1 Medical Device Clinical CROs: Distribution by Year of Establishment
Figure 4.2 Medical Device Clinical CROs: Distribution by Company Size
Figure 4.3 Medical Device Clinical CROs: Distribution by Location of Headquarters
Figure 4.4 Medical Device Clinical CROs: Distribution by Company Size and Location of Headquarters
Figure 4.5 Medical Device Clinical CROs: Distribution by Type of Service Offered
Figure 4.6 Medical Device Clinical CROs: Distribution by Year of Establishment, Type of Service Offered and Location of Headquarters
Figure 4.7 Medical Device Clinical CROs: Distribution by Types of Clinical Trial Management Services Offered
Figure 4.8 Medical Device Clinical CROs: Distribution by Types of Regulatory Services Offered
Figure 4.9 Medical Device Preclinical CROs: Distribution by Year of Establishment
Figure 4.10 Medical Device Preclinical CROs: Distribution by Company Size
Figure 4.11 Medical Device Preclinical CROs: Distribution by Location of Headquarters
Figure 4.12 Medical Device Preclinical CROs: Distribution by Company Size and Location of Headquarters
Figure 4.13 Medical Device Preclinical CROs: Distribution by Type of Service Offered
Figure 4.14 Medical Device Standalone CROs: Distribution by Year of Establishment
Figure 4.15 Medical Device Standalone CROs: Distribution by Company Size
Figure 4.16 Medical Device Standalone CROs: Distribution by Location of Headquarters
Figure 4.17 Medical Device Standalone CROs: Distribution by Company Size and Location of Headquarters
Figure 4.18 Medical Device Standalone CROs: Distribution by Type of Service Offered
Figure 5.1 Key Regulatory Authorities for Medical Devices
Figure 5.2 Medical Devices Review / Approval Process in the US
Figure 5.3 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 5.4 Medical Devices National Coverage Determination Process in the US
Figure 5.5 Medical Devices Review / Approval Process in Canada
Figure 5.6 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 5.7 Medical Devices Review / Approval Process in Mexico
Figure 5.8 Regulatory Bodies in EU5 Countries
Figure 5.9 Steps involved in CE Marking Process
Figure 5.10 Medical Devices Review / Approval Process in Europe
Figure 5.11 Medical Devices Review / Approval Process in the UK
Figure 5.12 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 5.13 Reimbursement Process for Medical Devices in the UK
Figure 5.14 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 5.15 Reimbursement Process for Medical Devices through List of Products and Services Qualifying for Reimbursement
Figure 5.16 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 5.17 Reimbursement Process for In-Patient Setting in Germany
Figure 5.18 Reimbursement Process for Out-Patient Care in Germany
Figure 5.19 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Figure 5.20 Reimbursement Process for Medical Devices in Italy
Figure 5.21 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 5.22 Reimbursement Process for Medical Devices in Spain
Figure 5.23 Medical Devices Review / Approval Process in Australia
Figure 5.24 Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
Figure 5.25 Medical Devices Review / Approval Process in Brazil
Figure 5.26 Reimbursement Process for Medical Devices in Brazil
Figure 5.27 Medical Devices Review / Approval Process in China
Figure 5.28 Healthcare Insurance Coverage in China: Distribution by Type of Coverage
Figure 5.29 Reimbursement Approval Process for Medical Devices in Shanghai
Figure 5.30 Medical Devices Review / Approval Process in India
Figure 5.31 Healthcare Insurance Coverage in Israel: Distribution by Type of Coverage
Figure 5.32 Medical Devices Review / Approval Process in Japan
Figure 5.33 Snapshot of the Regulatory and Reimbursement Process in Japan
Figure 5.34 Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
Figure 5.35 Reimbursement Process for New Medical Devices in Japan
Figure 5.36 Medical Devices Review / Approval Process in New Zealand
Figure 5.37 Healthcare Insurance Coverage in New Zealand: Distribution by Type of Coverage
Figure 5.38 Medical Devices Review / Approval Process in Singapore
Figure 5.39 Medical Devices Review / Approval Process in South Korea
Figure 5.40 Healthcare Insurance Coverage in South Korea: Distribution by Type of Coverage
Figure 5.41 Medical Devices Review / Approval Process in South Africa
Figure 5.42 Medical Devices Review / Approval Process in Taiwan
Figure 5.43 Healthcare Insurance Coverage in Taiwan: Distribution by Type of Coverage
Figure 5.44 Medical Devices Review / Approval Process in Thailand
Figure 5.45 Heat Map Analysis: Comparison of Regional Regulatory Control for Medical Devices
Figure 5.46 Regulatory Control for Medical Devices: Regional Analysis by Device Risk Category
Figure 6.1 Avania: Service Portfolio
Figure 6.2 Charles River Laboratories: Service Portfolio
Figure 6.3 Clinlogix: Service Portfolio
Figure 6.4 CROMSOURCE: Service Portfolio
Figure 6.5 CSSi LifeSciences: Service Portfolio
Figure 6.6 Eurofins Medical Device Testing: Service Portfolio
Figure 6.7 genae: Service Portfolio
Figure 6.8 IMARC Research: Service Portfolio
Figure 6.9 IQVIA: Service Portfolio
Figure 6.10 Medpace: Service Portfolio
Figure 6.11 NAMSA: Service Portfolio
Figure 6.12 Qserve Group: Service Portfolio:
Figure 6.13 Regulatory and Clinical Research Institute: Service Portfolio
Figure 6.14 WuXi AppTec: Service Portfolio
Figure 7.1 Key Attributes for Selection of Key Performance Indicators (KPIs)
Figure 7.2 Types of KPIs
Figure 7.3 Financial Indicators: Comparative Analysis of KPIs considered by Big Pharma Companies
Figure 7.4 Financial Indicators: Sponsors’ (Big Pharma) Perspective
Figure 7.5 Financial Indicators: Contract Service Providers’ Perspective
Figure 7.6 Process / Capability Indicators: Comparative Analysis of KPIs considered by Big Pharma Companies
Figure 7.7 Process / Capability Indicators: Sponsors’ (Big Pharma) Perspective
Figure 7.8 Process / Capability Indicators: Contract Service Providers’ Perspective
Figure 7.9 Market Reputation Indicators: Comparative Analysis of KPIs conssidered by Big Pharma Companies
Figure 7.10 Market Reputation Indicators: Sponsors’ (Big Pharma) Perspective
Figure 7.11 Market Reputation Indicators: Contract Service Providers’ Perspective
Figure 7.12 Comparison of Key Factors to be considered while selecting KPIs for Medical Devices
Figure 8.1 Competitive Benchmarking: Distribution by Region and Company Size
Figure 8.2 Competitive Benchmarking: North America, Peer Group I
Figure 8.3 Competitive Benchmarking: North America, Peer Group II
Figure 8.4 Competitive Benchmarking: North America, Peer Group III
Figure 8.5 Competitive Benchmarking: Europe, Peer Group IV
Figure 8.6 Competitive Benchmarking: Europe, Peer Group V
Figure 8.7 Competitive Benchmarking: Asia-Pacific, Peer Group VI
Figure 8.8 Competitive Benchmarking: Asia-Pacific, Peer Group VII
Figure 8.9 Competitive Benchmarking: Comparison of Services and Capabilities across Different Peer Groups
Figure 9.1 Brand Positioning of Key Industry Players
Figure 9.2 Brand Positioning Matrix: FMD K&L
Figure 9.2 Brand Positioning Matrix: ICON
Figure 9.3 Brand Positioning Matrix: NAMSA
Figure 9.4 Brand Positioning Matrix: PAREXEL International
Figure 9.5 Brand Positioning Matrix: PPD
Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, 2015-2020
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.4 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.5 Clinical Trial Analysis: Distribution by Geography
Figure 10.6 Clinical Trial Analysis: Geographical Distribution by Trial Status
Figure 10.7 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 10.8 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 10.9 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Figure 10.10 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 10.11 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Therapeutic Area
Figure 10.12 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Location of Trial Site
Figure 10.13 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Location of Trial Site
Figure 11.1 Mergers and Acquisitions: Cumulative Year-Wise Trend (2015-2020)
Figure 11.2 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Figure 11.3 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
Figure 11.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 11.5 Mergers and Acquisitions: Intercontinental and Intracontinental Acquisitions
Figure 11.6 Mergers and Acquisitions: Country-wise Distribution
Figure 11.7 Mergers and Acquisitions: Ownership Change Matrix
Figure 11.8 Mergers and Acquisitions: Distribution by Type of Company
Figure 11.9 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 11.10 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
Figure 12.1 Survey Insights: Distribution of Respondents by Company Size
Figure 12.2 Survey Insights: Distribution of Respondents by Location of Company Headquarters
Figure 12.3 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Figure 12.4 Survey Insights: Distribution of Respondents by Type of Service Offered
Figure 12.5 Survey Insights: Distribution of Respondents by Therapeutic Area
Figure 12.6 Survey Insights: Distribution of Respondents by Average Number of Projects
Figure 12.7 Survey Insights: Distribution of Respondents by Market Opportunity
Figure 13.1 Overall Medical Device CRO Market, 2020-2030 (USD Billion)
Figure 13.2 Medical Device CRO Market, 2020-2030: Distribution by Therapeutic Area (USD Billion)
Figure 13.3 Medical Device CRO Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.4 Medical Device CRO Market, 2020-2030: Distribution by Device Class (USD Billion)
Figure 13.5 Medical Device CRO Market, 2020-2030: Distribution by Type of Clinical Service Offered (USD Billion)
Figure 13.6 Medical Device CRO Market, 2020-2030: Distribution by Type of Preclinical Service Offered (USD Billion)
Figure 13.7 Medical Device CRO Market, 2020-2030: Distribution by Geography (USD Billion)
Figure 13.8 Medical Device CRO Market in North America, 2020-2030 (USD Billion)
Figure 13.9 Medical Device CRO Market for Bone Disorders in North America, 2020-2030 (USD Billion)
Figure 13.10 Medical Device CRO Market for Cardiovascular Disorders in North America, 2020-2030 (USD Billion)
Figure 13.11 Medical Device CRO Market for CNS Disorders in North America, 2020-2030 (USD Billion)
Figure 13.12 Medical Device CRO Market for Metabolic Disorders in North America, 2020-2030 (USD Billion)
Figure 13.13 Medical Device CRO Market for Oncological Disorders in North America, 2020-2030 (USD Billion)
Figure 13.14 Medical Device CRO Market for Ophthalmic Disorders in North America, 2020-2030 (USD Billion)
Figure 13.15 Medical Device CRO Market for Pain Management Disorders in North America, 2020-2030 (USD Billion)
Figure 13.16 Medical Device CRO Market for Respiratory Disorders in North America, 2020-2030 (USD Billion)
Figure 13.17 Medical Device CRO Market for Sleeping Disorders in North America, 2020-2030 (USD Billion)
Figure 13.18 Medical Device CRO Market for Other Therapeutic Areas in North America, 2020-2030 (USD Billion)
Figure 13.19 Medical Device CRO Market for Class I Devices in North America, 2020-2030 (USD Billion)
Figure 13.20 Medical Device CRO Market for Class II Devices in North America, 2020-2030 (USD Billion)
Figure 13.21 Medical Device CRO Market for Class III Devices in North America, 2020-2030 (USD Billion)
Figure 13.22 Medical Device CRO Market for Clinical Trial Management Services in North America, 2020-2030 (USD Billion)
Figure 13.23 Medical Device CRO Market for Consulting Services in North America, 2020-2030 (USD Billion)
Figure 13.24 Medical Device CRO Market for Data Management Services in North America, 2020-2030 (USD Billion)
Figure 13.25 Medical Device CRO Market for Regulatory Affairs Management Services in North America, 2020-2030 (USD Billion)
Figure 13.26 Medical Device CRO Market for Other Clinical Services in North America, 2020-2030 (USD Billion)
Figure 13.27 Medical Device CRO Market for Material Characterization and Analytical Services in North America, 2020-2030 (USD Billion)
Figure 13.28 Medical Device CRO Market for Biocompatibility Testing Services in North America, 2020-2030 (USD Billion)
Figure 13.29 Medical Device CRO Market for Sterility and Microbiology Testing Services in North America, 2020-2030 (USD Billion)
Figure 13.30 Medical Device CRO Market for Other Preclinical Services in North America, 2020-2030 (USD Billion)
Figure 13.31 Medical Device CRO Market in Europe, 2020-2030 (USD Billion)
Figure 13.32 Medical Device CRO Market for Bone Disorders in Europe, 2020-2030 (USD Billion)
Figure 13.33 Medical Device CRO Market for Cardiovascular Disorders in Europe, 2020-2030 (USD Billion)
Figure 13.34 Medical Device CRO Market for CNS Disorders in Europe, 2020-2030 (USD Billion)
Figure 13.35 Medical Device CRO Market for Metabolic Disorders in Europe, 2020-2030 (USD Billion)
Figure 13.36 Medical Device CRO Market for Oncological Disorders in Europe, 2020-2030 (USD Billion)
Figure 13.37 Medical Device CRO Market for Ophthalmic Disorders in Europe, 2020-2030 (USD Billion)
Figure 13.38 Medical Device CRO Market for Pain Management Disorders in Europe, 2020-2030 (USD Billion)
Figure 13.39 Medical Device CRO Market for Respiratory Disorders in Europe, 2020-2030 (USD Billion)
Figure 13.40 Medical Device CRO Market for Sleeping Disorders in Europe, 2020-2030 (USD Billion)
Figure 13.41 Medical Device CRO Market for Other Therapeutic Areas in Europe, 2020-2030 (USD Billion)
Figure 13.42 Medical Device CRO Market for Class I Devices in Europe, 2020-2030 (USD Billion)
Figure 13.43 Medical Device CRO Market for Class II Devices in Europe, 2020-2030 (USD Billion)
Figure 13.44 Medical Device CRO Market for Class III Devices in Europe, 2020-2030 (USD Billion)
Figure 13.45 Medical Device CRO Market for Clinical Trial Management Services in Europe, 2020-2030 (USD Billion)
Figure 13.46 Medical Device CRO Market for Consulting Services in Europe, 2020-2030 (USD Billion)
Figure 13.47 Medical Device CRO Market for Data Management Services in Europe, 2020-2030 (USD Billion)
Figure 13.48 Medical Device CRO Market for Regulatory Affairs Management Services in Europe, 2020-2030 (USD Billion)
Figure 13.49 Medical Device CRO Market for Other Clinical Services in Europe, 2020-2030 (USD Billion)
Figure 13.50 Medical Device CRO Market for Material Characterization and Analytical Services in Europe, 2020-2030 (USD Billion)
Figure 13.51 Medical Device CRO Market for Biocompatibility Testing Services in Europe, 2020-2030 (USD Billion)
Figure 13.52 Medical Device CRO Market for Sterility and Microbiology Testing Services in Europe, 2020-2030 (USD Billion)
Figure 13.53 Medical Device CRO Market for Other Preclinical Services in Europe, 2020-2030 (USD Billion)
Figure 13.54 Medical Device CRO Market in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.55 Medical Device CRO Market for Bone Disorders in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.56 Medical Device CRO Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.57 Medical Device CRO Market for CNS Disorders in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.58 Medical Device CRO Market for Metabolic Disorders in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.59 Medical Device CRO Market for Oncological Disorders in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.60 Medical Device CRO Market for Ophthalmic Disorders in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.61 Medical Device CRO Market for Pain Management Disorders in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.62 Medical Device CRO Market for Respiratory Disorders in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.63 Medical Device CRO Market for Sleeping Disorders in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.64 Medical Device CRO Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.65 Medical Device CRO Market for Class I Devices in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.66 Medical Device CRO Market for Class II Devices in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.67 Medical Device CRO Market for Class III Devices in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.68 Medical Device CRO Market for Clinical Trial Management Services in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.69 Medical Device CRO Market for Consulting Services in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.70 Medical Device CRO Market for Data Management Services in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.71 Medical Device CRO Market for Regulatory Affairs Management Services in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.72 Medical Device CRO Market for Other Clinical Services in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.73 Medical Device CRO Market for Material Characterization and Analytical Services in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.74 Medical Device CRO Market for Biocompatibility Testing Services in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.75 Medical Device CRO Market for Sterility and Microbiology Testing Services in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.76 Medical Device CRO Market for Other Preclinical Services in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.77 Medical Device CRO Market in Rest of the World, 2020-2030 (USD Billion)
Figure 13.78 Medical Device CRO Market for Bone Disorders in Rest of the World, 2020-2030 (USD Billion)
Figure 13.79 Medical Device CRO Market for Cardiovascular Disorders in Rest of the World, 2020-2030 (USD Billion)
Figure 13.80 Medical Device CRO Market for CNS Disorders in Rest of the World, 2020-2030 (USD Billion)
Figure 13.81 Medical Device CRO Market for Metabolic Disorders in Rest of the World, 2020-2030 (USD Billion)
Figure 13.82 Medical Device CRO Market for Oncological Disorders in Rest of the World, 2020-2030 (USD Billion)
Figure 13.83 Medical Device CRO Market for Ophthalmic Disorders in Rest of the World, 2020-2030 (USD Billion)
Figure 13.84 Medical Device CRO Market for Pain Management Disorders in Rest of the World, 2020-2030 (USD Billion)
Figure 13.85 Medical Device CRO Market for Respiratory Disorders in Rest of the World, 2020-2030 (USD Billion)
Figure 13.86 Medical Device CRO Market for Sleeping Disorders in Rest of the World, 2020-2030 (USD Billion)
Figure 13.87 Medical Device CRO Market for Other Therapeutic Areas in Rest of the World, 2020-2030 (USD Billion)
Figure 13.88 Medical Device CRO Market for Class I Devices in Rest of the World, 2020-2030 (USD Billion)
Figure 13.89 Medical Device CRO Market for Class II Devices in Rest of the World, 2020-2030 (USD Billion)
Figure 13.90 Medical Device CRO Market for Class III Devices in Rest of the World, 2020-2030 (USD Billion)
Figure 13.91 Medical Device CRO Market for Clinical Trial Management Services in Rest of the World, 2020-2030 (USD Billion)
Figure 13.92 Medical Device CRO Market for Consulting Services in Rest of the World, 2020-2030 (USD Billion)
Figure 13.99 Medical Device CRO Market for Data Management Services in Rest of the World, 2020-2030 (USD Billion)
Figure 13.94 Medical Device CRO Market for Regulatory Affairs Management Services in Rest of the World, 2020-2030 (USD Billion)
Figure 13.95 Medical Device CRO Market for Other Clinical Services in Rest of the World, 2020-2030 (USD Billion)
Figure 13.96 Medical Device CRO Market for Material Characterization and Analytical Services in Rest of the World, 2020-2030 (USD Billion)
Figure 13.97 Medical Device CRO Market for Biocompatibility Testing Services in Rest of the World, 2020-2030 (USD Billion)
Figure 13.98 Medical Device CRO Market for Sterility and Microbiology Testing Services in Rest of the World, 2020-2030 (USD Billion)
Figure 13.99 Medical Device CRO Market for Other Preclinical Services in Rest of the World, 2020-2030 (USD Billion)
Figure 14.1 Summary of Likely Impact of Coronavirus Pandemic on Medical Device Industry
Figure 15.1 Medical Device CRO Market: SWOT Analysis
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Future Trends and Opportunities for Medical Device CROs

List Of Tables

Table 3.1 Comparison of Key Factors Considered by Medical Device Developers for Selecting a CRO Partner: Harvey Ball Analysis
Table 4.1 Medical Device CROs: List of Clinical Service Providers
Table 4.2 Medical Device Clinical CROs: Information on Type of Service Offered
Table 4.3 Medical Device Clinical CROs: Information on Type of Clinical Trial Management Service Offered
Table 4.4 Medical Device Clinical CROs: Information on Type of Regulatory Service Offered
Table 4.5 Medical Device CROs: List of Preclinical Service Providers
Table 4.6 Medical Device Preclinical CROs: Information on Type of Service Offered
Table 4.7 Medical Device CROs: List of Standalone Service Providers
Table 5.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 5.2 Device Classification: US
Table 5.3 Device Classification: Canada
Table 5.4 Data Requirements and Characteristics of Province-wide HTA Processes in Canada
Table 5.5 Device Classification: Mexico
Table 5.6 Device Classification: Europe
Table 5.7 List of CE Directives in Europe
Table 5.8 Conformity Assessment Modules in Europe
Table 5.9 Device Classification: Australia
Table 5.10 Reimbursement and Pricing Approval Process of Medical devices in Australia
Table 5.11 Device Classification: Brazil
Table 5.12 Device Classification: China
Table 5.13 Device Classification: India
Table 5.14 Device Classification: Japan
Table 5.15 Medical Devices Reimbursement Categories
Table 5.16 Device Classification: New Zealand
Table 5.17 Device Classification: Singapore
Table 5.18 Device Classification: South Korea
Table 5.19 Device Classification: South Africa
Table 5.20 Device Classification: Thailand
Table 5.21 Medical Devices Regulatory Landscape Summary
Table 5.22 Medical Devices Reimbursement Landscape Summary
Table 6.1 Avania: Company Overview
Table 6.2 Avania: Future Outlook
Table 6.3 Charles River Laboratories: Company Overview
Table 6.4 Charles River Laboratories: Future Outlook
Table 6.5 Clinlogix: Company Overview
Table 6.6 Clinlogix: Future Outlook
Table 6.7 CROMSOURCE: Company Overview
Table 6.8 CROMSOURCE: Future Outlook
Table 6.9 CSSi Life Sciences: Company Overview
Table 6.10 Eurofins Medical Device Testing: Company Overview
Table 6.11 Eurofins Medical Device Testing: Future Outlook
Table 6.12 genae: Company Overview
Table 6.13 genae: Future Outlook
Table 6.14 IMARC Research: Company Overview
Table 6.15 IMARC Research: Future Outlook
Table 6.16 IQVIA: Company Overview
Table 6.17 IQVIA: Future Outlook
Table 6.18 Medpace: Company Overview
Table 6.19 Medpace: Future Outlook
Table 6.20 NAMSA: Company Overview
Table 6.21 NAMSA: Future Outlook
Table 6.22 Qserve Group: Company Overview
Table 6.23 Qserve Group: Future Outlook
Table 6.24 Regulatory and Clinical Research Institute: Company Overview
Table 6.25 Regulatory and Clinical Research Institute (Now a part of Covance): Future Outlook
Table 6.26 WuXi AppTec: Company Overview
Table 6.27 WuXi AppTec: Future Outlook
Table 8.1 Benchmark Analysis: Peer Groups
Table 11.1 Medical Device CRO Market: List of Mergers and Acquisitions, 2015-2020
Table 11.2 Acquisitions: Key Value Drivers
Table 12.1 Survey Insights: Overview of Respondents
Table 12.2 Survey Insights: Designation and Seniority Level of Respondents
Table 12.3 Survey Insights: Type of Service Offered
Table 12.4 Survey Insights: Therapeutic Area
Table 12.5 Survey Insights: Average Number of Projects
Table 12.6 Survey Insights: Market Opportunity
Table 18.1 Medical Device Clinical CROs: Distribution by Year of Establishment
Table 18.2 Medical Device Clinical CROs: Distribution by Company Size
Table 18.3 Medical Device Clinical CROs: Distribution by Location of Headquarters
Table 18.4 Medical Device Clinical CROs: Distribution by Company Size and Location of Headquarters
Table 18.5 Medical Device Clinical CROs: Distribution by Type of Service Offered
Table 18.6 Medical Device Clinical CROs: Distribution by Year of Establishment, Type of Service Offered and Location of Headquarters
Table 18.7 Medical Device Clinical CROs: Distribution by Types of Clinical Trial Management Services Offered
Table 18.8 Medical Device Clinical CROs: Distribution by Types of Regulatory Services Offered
Table 18.9 Medical Device Preclinical CROs: Distribution by Year of Establishment
Table 18.10 Medical Device Preclinical CROs: Distribution by Company Size
Table 18.11 Medical Device Preclinical CROs: Distribution by Location of Headquarters
Table 18.12 Medical Device Preclinical CROs: Distribution by Company Size and Location of Headquarters
Table 18.13 Medical Device Preclinical CROs: Distribution by Type of Service Offered
Table 18.14 Medical Device Standalone CROs: Distribution by Year of Establishment
Table 18.15 Medical Device Standalone CROs: Distribution by Company Size
Table 18.16 Medical Device Standalone CROs: Distribution by Location of Headquarters
Table 18.17 Medical Device Standalone CROs: Distribution by Company Size and Location of Headquarters
Table 18.18 Medical Device Standalone CROs: Distribution by Type of Service Offered
Table 18.19 Clinical Trial Analysis: Distribution by Trial Registration Year, 2015-2020
Table 18.20 Clinical Trial Analysis: Distribution by Trial Status
Table 18.21 Clinical Trial Analysis: Distribution by Trial Phase
Table 18.22 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 18.23 Clinical Trial Analysis: Geographical Distribution by Trial Status
Table 18.24 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 18.25 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 18.26 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Table 18.27 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 18.28 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Therapeutic Area
Table 18.29 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Location of Trial Site
Table 18.30 Mergers and Acquisitions: Cumulative Year-Wise Trend (2015-2020)
Table 18.31 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Table 18.32 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
Table 18.33 Mergers and Acquisitions: Continent-wise Distribution
Table 18.34 Mergers and Acquisitions: Country-wise Distribution
Table 18.35 Mergers and Acquisitions: Ownership Change Matrix
Table 18.36 Mergers and Acquisitions: Distribution by Type of Company
Table 18.37 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 18.38 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
Table 18.39 Survey Insights: Distribution of Respondents by Company Size
Table 18.40 Survey Insights: Distribution of Respondents by Location of Company Headquarters
Table 18.41 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Table 18.42 Survey Insights: Distribution of Respondents by Type of Service Offered
Table 18.43 Survey Insights: Distribution of Respondents by Therapeutic Area
Table 18.44 Survey Insights: Distribution of Respondents by Average Number of Projects
Table 18.45 Survey Insights: Distribution of Respondents by Market Opportunity
Table 18.46 Overall Medical Device CRO Market, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.47 Medical Device CRO Market, 2020-2030: Distribution by Therapeutic Area (USD Billion)
Table 18.48 Medical Device CRO Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Table 18.49 Medical Device CRO Market, 2020-2030: Distribution by Device Class (USD Billion)
Table 18.50 Medical Device CRO Market, 2020-2030: Distribution by Type of Clinical Service Offered (USD Billion)
Table 18.51 Medical Device CRO Market, 2020-2030: Distribution by Type of Preclinical Service Offered (USD Billion)
Table 18.52 Medical Device CRO Market, 2020-2030: Distribution by Geography (USD Billion)
Table 18.53 Medical Device CRO Market in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.54 Medical Device CRO Market for Bone Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.55 Medical Device CRO Market for Cardiovascular Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.56 Medical Device CRO Market for CNS Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.57 Medical Device CRO Market for Metabolic Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.58 Medical Device CRO Market for Oncological Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.59 Medical Device CRO Market for Ophthalmic Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.60 Medical Device CRO Market for Pain Management Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.61 Medical Device CRO Market for Respiratory Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.62 Medical Device CRO Market for Sleeping Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.63 Medical Device CRO Market for Other Therapeutic Areas in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.64 Medical Device CRO Market for Class I Devices in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.65 Medical Device CRO Market for Class II Devices in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.66 Medical Device CRO Market for Class III Devices in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.67 Medical Device CRO Market for Clinical Trial Management Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.68 Medical Device CRO Market for Consulting Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.69 Medical Device CRO Market for Data Management Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.70 Medical Device CRO Market for Regulatory Affairs Management Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.71 Medical Device CRO Market for Other Clinical Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.72 Medical Device CRO Market for Material Characterization and Analytical Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.73 Medical Device CRO Market for Biocompatibility Testing Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.74 Medical Device CRO Market for Sterility and Microbiology Testing Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.75 Medical Device CRO Market for Other Preclinical Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.76 Medical Device CRO Market in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.77 Medical Device CRO Market for Bone Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.78 Medical Device CRO Market for Cardiovascular Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.79 Medical Device CRO Market for CNS Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.80 Medical Device CRO Market for Metabolic Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.81 Medical Device CRO Market for Oncological Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.82 Medical Device CRO Market for Ophthalmic Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.83 Medical Device CRO Market for Pain Management Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.84 Medical Device CRO Market for Respiratory Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.85 Medical Device CRO Market for Sleeping Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.86 Medical Device CRO Market for Other Therapeutic Areas in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.87 Medical Device CRO Market for Class I Devices in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.88 Medical Device CRO Market for Class II Devices in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.89 Medical Device CRO Market for Class III Devices in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.90 Medical Device CRO Market for Clinical Trial Management Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.91 Medical Device CRO Market for Consulting Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.92 Medical Device CRO Market for Data Management Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.93 Medical Device CRO Market for Regulatory Affairs Management Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.94 Medical Device CRO Market for Other Clinical Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.95 Medical Device CRO Market for Material Characterization and Analytical Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.96 Medical Device CRO Market for Biocompatibility Testing Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.97 Medical Device CRO Market for Sterility and Microbiology Testing Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.98 Medical Device CRO Market for Other Preclinical Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.99 Medical Device CRO Market in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.100 Medical Device CRO Market for Bone Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.101 Medical Device CRO Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.102 Medical Device CRO Market for CNS Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.103 Medical Device CRO Market for Metabolic Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.104 Medical Device CRO Market for Oncological Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.105 Medical Device CRO Market for Ophthalmic Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.106 Medical Device CRO Market for Pain Management Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.107 Medical Device CRO Market for Respiratory Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.108 Medical Device CRO Market for Sleeping Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.109 Medical Device CRO Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.110 Medical Device CRO Market for Class I Devices in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.111 Medical Device CRO Market for Class II Devices in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.112 Medical Device CRO Market for Class III Devices in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.113 Medical Device CRO Market for Clinical Trial Management Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.114 Medical Device CRO Market for Consulting Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.115 Medical Device CRO Market for Data Management Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.116 Medical Device CRO Market for Regulatory Affairs Management Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.117 Medical Device CRO Market for Other Clinical Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.118 Medical Device CRO Market for Material Characterization and Analytical Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.119 Medical Device CRO Market for Biocompatibility Testing Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.120 Medical Device CRO Market for Sterility and Microbiology Testing Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.121 Medical Device CRO Market for Other Preclinical Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.122 Medical Device CRO Market in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.123 Medical Device CRO Market for Bone Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.124 Medical Device CRO Market for Cardiovascular Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.125 Medical Device CRO Market for CNS Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.126 Medical Device CRO Market for Metabolic Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.127 Medical Device CRO Market for Oncological Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.128 Medical Device CRO Market for Ophthalmic Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.129 Medical Device CRO Market for Pain Management Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.130 Medical Device CRO Market for Respiratory Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.131 Medical Device CRO Market for Sleeping Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.132 Medical Device CRO Market for Other Therapeutic Areas in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.133 Medical Device CRO Market for Class I Devices in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.134 Medical Device CRO Market for Class II Devices in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.135 Medical Device CRO Market for Class III Devices in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.136 Medical Device CRO Market for Clinical Trial Management Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.137 Medical Device CRO Market for Consulting Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.138 Medical Device CRO Market for Data Management Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.139 Medical Device CRO Market for Regulatory Affairs Management Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.140 Medical Device CRO Market for Other Clinical Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.141 Medical Device CRO Market for Material Characterization and Analytical Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.142 Medical Device CRO Market for Biocompatibility Testing Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.143 Medical Device CRO Market for Sterility and Microbiology Testing Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.144 Medical Device CRO Market for Other Preclinical Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 1MED SA
  2. 4Clinics
  3. A+ Science
  4. Abbott
  5. Abiogenesis Clinpharm
  6. Abond CRO (formerly known as QST Consultations)
  7. Absorption Systems
  8. ABX-CRO
  9. Acceliant 
  10. Accell Clinical Research
  11. AccelLAB
  12. Accelovance
  13. Accredited Consultants 
  14. AccuLab Life Sciences
  15. Accuprec Research Labs
  16. Accutest Research Laboratories
  17. Acorn Regulatory Consultancy Services
  18. Acrapack
  19. acromion
  20. aCROss Medical
  21. Activa Cro
  22. ADAX International
  23. Advanced Medical Research
  24. Advena
  25. Affinity Bio Partners
  26. Afra Pharma Consultant
  27. AGINKO Research
  28. AICROS
  29. AJW Technology Consultants
  30. AKRN Scientific Consulting
  31. Al Tamimi
  32. Allied Clinical Management
  33. Altair Clinical
  34. Altiora
  35. AMANO Clinical Consulting
  36. Amarex Clinical Research
  37. American Preclinical Services
  38. AmeRuss 
  39. Amritt 
  40. Amulet Capital Partners
  41. analyze & realize
  42. Andaman Medical
  43. anteris medical
  44. ANTRIX
  45. A-pharmaconsult
  46. apices
  47. APO Plus Station
  48. Appletree CI Group
  49. Arazy Group Consultants
  50. Archemin
  51. ARQon
  52. Asia Actual
  53. Asiatic Clinical Research
  54. ATLANSTAT
  55. AtoZ-CRO
  56. Auriga Research
  57. Australian Healthcare Solutions
  58. Auxilife Scientific Services
  59. Avania (formerly known as Factory CRO)
  60. AVANTI
  61. AVIAD Life Sciences
  62. Axonal-Biostatem
  63. Azelix
  64. Barons Medical Consulting
  65. Beaufort
  66. Beijing JRJ Science and Technology
  67. BIC Group
  68. BioAgile Therapeutics
  69. Biocodex Nordics 
  70. Biomapas
  71. Biomedical Regulatory Consulting
  72. Biomedical Strategy 
  73. Bioneeds
  74. BioPlan
  75. Biorasi
  76. Bioreg Services
  77. Bioscience
  78. Biotech Regulatory Solutions
  79. BioTeknica 
  80. BiTrial Clinical Research
  81. BLAU Pharmaceutical Service
  82. BLS laboratories
  83. Boston Biomedical Associates
  84. Boston MedTech Advisors 
  85. Boston Scientific
  86. Brandwood CKC
  87. Bridge Pharm
  88. BRIDGE PTS
  89. Cactus Life Sciences
  90. Cardinal Health
  91. CardioMed Device Consultants 
  92. Cardiovascular European Research Center
  93. CARE Research
  94. Caritas Clinical 
  95. CARSL Consulting 
  96. Catalyst Regulatory Services
  97. Catawba Research
  98. Cato Research
  99. CBSET
  100. CC Clinical research Consultants
  101. C'en Al Research
  102. CERES
  103. Charles River Laboratories
  104. Chemical Inspection and Regulation Service
  105. Chiltern
  106. China Med Device
  107. Chris Freer Associates 
  108. Citoxlab
  109. Clarivate Analytics 
  110. ClinAudits
  111. ClinDatrix
  112. Clinical Device Group
  113. Clinical Research & Compliance Consulting
  114. Clinical Research Services (CRS)
  115. Clinical Trial Data Services
  116. CliniExperts
  117. Clinilabs
  118. Clinipace 
  119. CLINIQAL™ International
  120. Clinlogix
  121. Clinmark
  122. ClinMed Pharma
  123. Clinnex 
  124. ClinSync
  125. Cmed
  126. CMIC Group
  127. CMX Research
  128. Cobridge
  129. Commercial Eyes
  130. ComplianceAcuity
  131. CONET
  132. Consultys
  133. Convex
  134. Costello Medical 
  135. Courante Oncology
  136. Covance
  137. CPS Cortex
  138. Criterium
  139. Cromos Pharma
  140. CROMSOURCE
  141. CROS NT
  142. Crown CRO
  143. CSSi LifeSciences™
  144. CTI
  145. CTNT
  146. CurAccel
  147. Cvigilance 
  148. CW Research & Management
  149. CYA Medical Device Consulting
  150. Dalia Givony, Regulatory & Clinical Consulting
  151. Databean
  152. Datapharm Australia
  153. De Groot Technical Services
  154. DEKRA
  155. Denothex
  156. Devicia
  157. DFS Pharma
  158. DH RegSys
  159. dicentra
  160. DKSH Marketing Services Spain
  161. dMed
  162. dn8 collaborate
  163. Donawa Lifescience Consulting
  164. Dor Pharmaceutical Services
  165. Dove Quality Solutions
  166. DP Clinical
  167. DSA Consultants
  168. DZS Clinical Services
  169. EAS Consulting Group
  170. EG Mont
  171. Element
  172. Emergent Clinical Consulting
  173. En Pointe Clinical Research
  174. Engel, Hellyer & Partners 
  175. e-novex
  176. EPIC CRO Research
  177. Essilor
  178. ESTERN Medical
  179. Ethicare 
  180. EuDRAcon 
  181. Eurofins Medical Device Testing 
  182. Evidilya
  183. Exalon 
  184. FDAInsight
  185. FGK Clinical Research
  186. Firma Clinical Research
  187. Five Corners
  188. FMD K&L
  189. Focal Point Research
  190. Fountain Medical Development
  191. Fresenius Medical Care
  192. Frestedt
  193. Freyr
  194. Gateway
  195. GCP-Service International
  196. GE Healthcare
  197. genae
  198. Genco Medical
  199. Genelife Clinical Research
  200. Genpact
  201. George Clinical
  202. Getz Healthcare
  203. GKM
  204. Global Center for Medical Innovation
  205. Global Pharma Tek
  206. Global Regulatory Affairs
  207. Global Regulatory Partners
  208. Global Regulatory Services
  209. Grove Group
  210. Gsap
  211. Hangzhou Tigermed Consulting
  212. Healthcare International Partners
  213. HealthLink
  214. Hilbert Paradox
  215. Hinge Clinica
  216. HungaroTrial
  217. I3CGLOBAL
  218. IBEX Preclinical Research
  219. ICBio 
  220. ICON
  221. ICRC-Weyer
  222. ICTA
  223. IDConic
  224. Illingworth Research Group
  225. IMARC Research
  226. Inamed
  227. Innomar Strategies (a part of AmerisourceBergen)
  228. Inotiv
  229. InrexTest
  230. Integrated Resource
  231. International HealthCare
  232. Intertek Group
  233. Ipsum
  234. IQVIA
  235. Iris Pharma
  236. Ironstone Product Development
  237. IRW
  238. ISA HEALTH
  239. ITEC Services
  240. iuvo
  241. IVD Consultants
  242. IVDeology
  243. IZiel Healthcare
  244. J. Knipper 
  245. Japan MDC
  246. Johnson & Johnson
  247. JSS Medical Research
  248. Jyton
  249. KCR
  250. KCRI
  251. KD&A
  252. Ken Block Consulting
  253. Kensington Swan 
  254. Keystone Regulatory Services
  255. Kinapse
  256. KLIFO
  257. Knoell
  258. Kobridge Consulting
  259. KPS Clinical Services
  260. L.S Marketing & Registration
  261. LabCorp
  262. Lahav C.R.O
  263. Lambda Therapeutic Research 
  264. Larix
  265. Lean RAQA
  266. Leon Research
  267. Li-Med RA & QA Experts
  268. Linical Accelovance Group
  269. LINK Medical
  270. Lionbridge 
  271. Liveon Biolabs
  272. LNAge
  273. Macnair Consultants
  274. Made Consulting
  275. MakroCare
  276. Malca Chen-Zion
  277. MANDALA International
  278. MasterControl
  279. MAXIS
  280. McCarthy Consultant Services
  281. MD101 Consulting
  282. MD-Clinicals
  283. mdi Consultants
  284. mdi Europa
  285. MDP Solutions
  286. MED Institute
  287. Medanex Clinic
  288. Medelis
  289. Medfiles
  290. Medical Equipment Compliance Associates
  291. Medicomp
  292. MedicSense
  293. Medidee
  294. MediqTrans
  295. MEDITRIAL
  296. Meditrial MedTech Universe
  297. MedNet
  298. Medpace
  299. MedPass International
  300. MedQ Consultants
  301. Medtronic 
  302. MedVigil
  303. Medvinbio Labs
  304. Mene Research
  305. Mericon
  306. Meshayu Consultants
  307. MethodSense
  308. Metrics Research
  309. MIC Medical
  310. Micren Healthcare
  311. Mid-Link Consulting
  312. MileStone Research
  313. Mn Solutions
  314. Mobius Medical 
  315. Morley Research Consortium
  316. Morula HealthTech
  317. MPI Research
  318. Musculoskeletal Clinical Regulatory Advisers
  319. NAMSA
  320. Navitas Life Sciences
  321. NCGS
  322. Nelson Labs
  323. NEOMED Services
  324. Neometrix Consulting
  325. Neopharm
  326. Neox Clinical Research
  327. Neozene
  328. Nerac
  329. New England Research Institutes
  330. Noble Life Sciences
  331. Northlane Capital Partners
  332. Novartis
  333. NovaTrials
  334. Novem Healthcare
  335. Novum
  336. NoyMed
  337. NSF International
  338. Nuvisan Pharma Services
  339. Nyprax Pharma
  340. O4 Research
  341. Obelis Group
  342. Odelle Technology
  343. Onorach
  344. Operon Strategist
  345. OPIS
  346. Optimal Pharm/Tox Consulting
  347. Optimal Research
  348. Optimapharm
  349. Ora
  350. Osmunda
  351. OThree Consulting
  352. Pace Analytical
  353. Pacific BioLabs
  354. Pacific Bridge Medical
  355. Pacific Clinical Research Group
  356. Pamplona Capital Management
  357. PAREXEL International
  358. PaxMed International 
  359. Pearl Pathways
  360. Pepgra
  361. Perfect Pharmaceuticals Consultants 
  362. Perfection-CRO
  363. Pharmaceutical Regulatory Services 
  364. Pharmaceutical Solutions
  365. Pharmahungary Group
  366. PharmaLex
  367. PharmaMed Research
  368. Pharmaseed
  369. PharmDedict 
  370. PharmEng Regulatory Affairs
  371. PharmOut
  372. Phidea Group
  373. Pilgrim Quality Solutions
  374. Pine Lake Laboratories
  375. Pivotal
  376. PMI Preclinical
  377. PPD
  378. PQE Group
  379. PRA Health Sciences
  380. PRADO
  381. PRC Clinical
  382. Precision Medicine Group
  383. Preclinical Medevice Innovations
  384. PreClinical Pathfinder
  385. PreClinical Research Services
  386. Premier Research
  387. Professionals Regulatory Affairs
  388. Profil 
  389. Promedica International
  390. ProMedoss
  391. ProPharma Group
  392. Prosoft Clinical
  393. ProTrials
  394. Proxima Clinical Research
  395. PRSG - Pharmaceutical and Regulatory Services 
  396. Q&R Canada
  397. QA Consulting
  398. QAdvis
  399. Qmed Consulting
  400. Qserve Group
  401. Q-Trials
  402. Qualitiso
  403. Quality and Compliance Consulting
  404. Qualtech Consulting
  405. Quanticate
  406. QUNIQUE 
  407. R & C Consulting 
  408. R&G PharmaStudies
  409. R.G.L Research
  410. RAMED
  411. Ratos
  412. RCQ Solutions
  413. RCRI (now a part of Covance)
  414. Reg-Affairs & QualiPractixis
  415. Regulatory and Quality Solutions
  416. Regulatory Compliance Associates
  417. Regulatory Insight
  418. Reimbursement Strategies
  419. Research Professionals
  420. Rho
  421. RJR Consulting
  422. RMF Clinical 
  423. Rook Quality Systems
  424. RQMIS
  425. RQSolutions
  426. RTI Health Solutions 
  427. Scandinavian CRO
  428. Scandinavian Regulatory Services AB
  429. SCIderm
  430. Scope International
  431. SeerPharma
  432. Sentez-CRO
  433. Seoul CRO
  434. SEQ
  435. SGS
  436. Shanghai QiSheng Business Consulting
  437. Shenzhen Advanced Medical Services
  438. Sidley Austin
  439. Siemens
  440. Simmons & Simmons
  441. Sipra Labs
  442. Sixmurs Group
  443. SMS-oncology
  444. Southern Star Research
  445. Sparta Systems
  446. SPharm
  447. SPRIM Advanced Life Sciences
  448. StarFish Medical
  449. STATKING Clinical Services 
  450. SteriPack Contract Manufacturing
  451. SterlingBio
  452. Strategic Compliance International
  453. StrugoPharm
  454. Stryker
  455. Sumika Chemical Analysis Service
  456. SunFlare
  457. Surpass
  458. Surpass-Silicon Valley
  459. Symbion Research
  460. Symbioteq 
  461. Syneos Health
  462. Syntax
  463. Synteract
  464. TAB Clinical
  465. Target Health
  466. TCA Clinical Research
  467. TechnoSTAT
  468. TentaMedix (formerly MicroMol)
  469. The Clinical Trial Company 
  470. The CRO Group
  471. The Medical Affairs Company
  472. The Weinberg Group
  473. THEMA
  474. Theo Manufacturing 
  475. Theorem Clinical Research
  476. TheraGenesis
  477. ThreeWire
  478. Toxikon
  479. TPIreg
  480. TransPerfect Life Sciences
  481. Trial Form Support International
  482. TriMetis
  483. Turacoz Healthcare Solutions
  484. TÜV SÜD - Healthcare & Medical Devices
  485. Ulmer Ventures
  486. Underwriters Laboratories
  487. Unikal Consultants
  488. Vantage BioTrials
  489. Vantage Consulting
  490. Venn Life Sciences
  491. Veristat
  492. Vimta
  493. vivo Science (a Texcell company)
  494. Vivotecnia
  495. Voler Biotech Consulting
  496. Vyomus Consulting
  497. WCCT Global
  498. WDB Holdings
  499. Wipro
  500. Wonderville
  501. WOODLEY BIOREG
  502. WuXi AppTec
  503. ZEINCRO
  504. Zi-Medical
  505. Zimmer Biomet
  506. Zwiers Regulatory Consultancy

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com